Sensei Biotherapeutics Q2 revenue down 55%, solnerstotug data favorable.

• Sensei Biotherapeutics reports Q2 2025 financial results and corporate update. • Full data for Phase 1/2 dose expansion cohort expected by year-end 2025. • Cash runway into second quarter of 2026. • Solnerstotug demonstrates favorable safety profile in Phase 1/2 study. • Combination with cemiplimab shows no significant additional toxicity.

BOSTON, July 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics, has reported its Q2 2025 financial results and provided updates on its clinical programs. The company's lead candidate, solnerstotug (SNS-101), showed promising results in its Phase 1/2 trial, demonstrating a favorable safety profile in combination with cemiplimab.

The financial highlights include a cash position of $28.6 million as of June 30, 2025, which is expected to fund operations into Q2 2026. The company reported a reduced net loss of $4.9 million compared to $7.1 million in Q2 2024, with decreased R&D expenses of $2.5 million and G&A expenses of $2.7 million. Full data from the Phase 1/2 dose expansion cohort is expected by year-end 2025, with upcoming presentation at the ESMO Congress 2025 in October.

Solnerstotug demonstrates encouraging progress in PD-(L)1 resistant tumors with a manageable safety profile. The drug's mechanism represents a differentiated approach in immuno-oncology by specifically activating within tumors, potentially addressing resistance to current checkpoint inhibitors. The completed enrollment of 64 patients in the Phase 1/2 expansion cohort, with 41 of 44 patients in the "hot" tumor cohort having progressed after prior PD-(L)1 therapy, is significant. The preliminary data showed favorable activity in these resistant patients while maintaining a manageable safety profile with primarily Grade 1-2 adverse events and no dose-limiting toxicities.

The company's strategy to pursue multiple Phase 2 studies across PD-(L)1 resistant tumor types is scientifically sound. By targeting VISTA, which correlates with poor prognosis, solnerstotug offers a novel approach to treating difficult-to-treat tumors.

References:
[1] https://stockanalysis.com/stocks/snse/
[2] https://www.stocktitan.net/news/SNSE/sensei-biotherapeutics-reports-second-quarter-2025-financial-results-mbs4nr88yfc9.html